Trial Profile
A two stage randomized, open label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered dose inhalers] adminstered either as fixed or as an adjustable regimen versus a fixed regimen of advair [salmeterol/fluticasone propionate] in subjects 12 yrs of age and older with asthma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2010
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary) ; Salmeterol/fluticasone propionate
- Indications Asthma
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
- 17 Apr 2008 New trial record.